World Health Organization: cessation of trials for the treatment of hospitalized corona patients using hydroxylchloroquine

The World Health Organization announced the cessation of trials for the treatment of hospitalized corona patients using hydroxylchloroquine or cocktail drug for lupinavir and ritonavir AIDS as they have not been shown to help reduce the effects of corona virus.
 The World Health Organization decision does not include other studies that use the drugs in question that are not hospitalized.
At the time, President Trump had been using Teva's hydroxilocloroquine for about two weeks even though he had not contracted the virus. During this period, Teva's shares rose, and its management stopped negotiations with the administration on an arrangement regarding the coordination of drugs that Teva was involved in. A number of research centers are still undergoing drug testing. With this, the health care organization that has denied the drug to hospitalized patients is still investigating the effects of the three drugs on patients who have not yet been hospitalized. There is currently only one FDA-approved drug. This is the remedies remedy of Gilead.